Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: Implications for personalized chemoprevention and therapy

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1946-1954

  Gold, Kathryn A ^a   Kim, Edward S ^a,b   Liu, Diane D ^a   Yuan, Ping ^a,b   Behrens, Carmen ^a   Solis, Luisa M ^a,b   Kadara, Humam ^a   Rice, David C ^a   Wistuba, Ignacio I ^a   Swisher, Stephen G ^a   Hofstetter, Wayne L ^a   Lee, J Jack ^a   Hong, Waun K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Sucre   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CHEMOKINE RECEPTOR CXCR2; DEOXYRIBONUCLEASE I; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELL ADHESION MOLECULE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MINICHROMOSOME MAINTENANCE PROTEIN 6; OSTEOPONTIN; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DNA METABOLISM; DNA REPAIR; DNA REPLICATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MICROSCOPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOPROPHYLAXIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PERSONALIZED MEDICINE; PROTEIN SYNTHESIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOPREVENTION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROTEIN BIOSYNTHESIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898735133     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1959     Document Type: Article

References (46)

1. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26. (Pubitemid 47073532)
2. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila Pa) 2008;1:250-4.
3. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-6. (Pubitemid 351161249)
4. De Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007;132:1932-8.
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
6. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8. (Pubitemid 46294612)
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
8. Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, et al. Overexpression of osteopontin, αβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PLoS One 2012;7:e48575.
9. Chaves-Pérez A, Mack B, Maetzel D, Kremling H, Eggert C, Harréus U, et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 2012;32:641-5.
10. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, et al. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 2010;9:1755-63.
11. Sun H, Chung WC, Ryu SH, Ju Z, Tran HT, Kim E, et al. Cyclic AMP-responsive element binding protein- and nuclear factor-κB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila) 2008;1:316-28.
12. Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, et al. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res 2009;69:7439-48.
13. Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, et al. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology 2011;152:2164-73.
14. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic impact of insulin receptor expression on survival of patients with non-small cell lung cancer. Cancer 2012;118:2454-65.
15. Morgillo F, Woo JK, Kim ES, Hong WK, Lee H-Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006;66:10100-11. (Pubitemid 44672064)
16. Tang X-M, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008;1:192-200.
17. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 2006;66:11194-206. (Pubitemid 46009947)
18. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007;67:11630-9.
19. Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, et al. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila) 2008;1:577-87.
20. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, et al. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 2012;23:78-85.
21. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) 2009;2:702-11.
22. Kadara H, Behrens C, Yuan P, Solis L, Liu D, GuX, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 2011;17:1490-501.
23. Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, et al. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res 2008;14:41-7. (Pubitemid 351377976)
24. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008;14:6014-22.
25. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, et al. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res 2010;16:34-44.
26. Harrel F. Regression modeling strategies. New York: Springer-Verlag; 2001.
27. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
28. Ephron B, Tibishirani R. Improvements on cross-validation: the .632+ bootstrap method. JASA 1997;92:548-60.
29. Harrell FE. Regression modeling strategies, with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag; 2011.
30. Lee JJ, Wu X, Hildebrandt MA, Yang H, Khuri FR, Kim E, et al. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 2011;4:185-93.
31. Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila Pa) 2010;3:597-603.
32. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009;136:2127-36 e1.
33. Shedden K, Taylor JMG, Enkemann SA, Tsao M-S, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Med 2008;14:822-7.
34. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, et al. Ep-CAM expression in pancreatic andampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008;61:31-5. (Pubitemid 351158222)
35. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 2004;10:2659-69. (Pubitemid 38509139)
36. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, et al. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int 2006;98:445-51.
37. Nakagawa M, Uramoto H, Oka S, Chikaishi Y, Iwanami T, Shimokawa H, et al. Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer 2012;13:136-42.
38. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
39. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
40. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-8.
41. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67. (Pubitemid 46801555)
42. Prins MJ, Verhage RJ, Ruurda JP, ten Kate FJ, van Hillegersberg R. Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2013;66:224-8.
43. Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, et al. High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 2009;15:4157-64.
44. Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, Kim YH, et al. Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 2012;460:601-9.
45. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-41.
46. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26. (Pubitemid 32295062)